Subtypes and beyond: naming and describing diffuse large B-cell lymphoma in an era of many treatments

Diffuse large B-cell lymphoma (DLBCL) comprises biologically diverse tumors. Cell-of-origin, dark-zone and genetic subtypes provide a valuable shared language that increasingly informs clinical trials and treatment selection. Independently developed genetic classifiers identify remarkably similar subtypes but disagree at their boundaries, reflecting biological overlap, differences in discovery cohorts and variation in mutation detection and interpretation. Moreover, existing categories compress biological complexity and capture only part of the information relevant to treatment response. Recent advances reveal complementary dimensions of DLBCL biology, including the non-coding regulatory genome, proteomic and post-translational features, the tumor microenvironment, malignant-cell state, clonal evolution and spatial organization. These dimensions provide information partly independent of existing classifications, as illustrated by a MYC-active proteomic group associated with early R-CHOP failure across genetic subtypes, an oligomannose-defined group within GCB DLBCL, and microenvironment archetypes associated with different outcomes after immunochemotherapy and CAR-T. As therapeutic options diversify, these additional dimensions become increasingly relevant, but do not by themselves warrant new subtypes. Instead, their clinical relevance depends on the treatment under consideration. We propose three complementary levels of characterization: naming tumors using robust categories suitable for routine diagnostic use; describing individual tumors through standardized, multidimensional molecular and clinical data; and ultimately forecasting treatment-specific outcomes. Much of this requires agreement rather than discovery: harmonized mutation calling, retention of underlying molecular data and pooling of trial datasets linked to treatment and outcome. As the repertoire of effective but increasingly costly therapies expands, molecular characterization must keep pace to ensure these treatments are deployed where they offer greatest benefit.

Authors

Publication Details

Journal
Apollo
Published
2026-11-21
DOI
https://doi.org/10.17863/cam.137004
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Subtypes and beyond: naming and describing diffuse large B-cell lymphoma in an era of many treatments

Daniel James Hodson
Apollo
Lymphoma Diagnosis and Treatment
article

Subtypes and beyond: naming and describing diffuse large B-cell lymphoma in an era of many treatments

Daniel James Hodson
article en

Abstract

Diffuse large B-cell lymphoma (DLBCL) comprises biologically diverse tumors. Cell-of-origin, dark-zone and genetic subtypes provide a valuable shared language that increasingly informs clinical trials and treatment selection. Independently developed genetic classifiers identify remarkably similar subtypes but disagree at their boundaries, reflecting biological overlap, differences in discovery cohorts and variation in mutation detection and interpretation. Moreover, existing categories compress biological complexity and capture only part of the information relevant to treatment response. Recent advances reveal complementary dimensions of DLBCL biology, including the non-coding regulatory genome, proteomic and post-translational features, the tumor microenvironment, malignant-cell state, clonal evolution and spatial organization. These dimensions provide information partly independent of existing classifications, as illustrated by a MYC-active proteomic group associated with early R-CHOP failure across genetic subtypes, an oligomannose-defined group within GCB DLBCL, and microenvironment archetypes associated with different outcomes after immunochemotherapy and CAR-T. As therapeutic options diversify, these additional dimensions become increasingly relevant, but do not by themselves warrant new subtypes. Instead, their clinical relevance depends on the treatment under consideration. We propose three complementary levels of characterization: naming tumors using robust categories suitable for routine diagnostic use; describing individual tumors through standardized, multidimensional molecular and clinical data; and ultimately forecasting treatment-specific outcomes. Much of this requires agreement rather than discovery: harmonized mutation calling, retention of underlying molecular data and pooling of trial datasets linked to treatment and outcome. As the repertoire of effective but increasingly costly therapies expands, molecular characterization must keep pace to ensure these treatments are deployed where they offer greatest benefit.

Apollo
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Subtypes and beyond: naming and describing diffuse large B-cell lymphoma in an era of many treatments — Daniel James Hodson · Apollo (2026) | TGRS Research Map | TGRS